CLZ-8
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].
Product Specifications
CAS Number
678158-55-9
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/clz-8.html
Purity
99.14
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3
Molecular Formula
C22H23N3O2S
Molecular Weight
393.50
References & Citations
[1]Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8 (33) :54236-54242.|[2]Feng T, et al. CLZ-8, a potent small-molecular compound, protects radiation-induced damages both in vitro and in vivo. Environ Toxicol Pharmacol. 2018 Jul;61:44-51.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Mcl-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
T8069-95D-Biotin 100 µL
Toxic Shock Syndrome Toxin (TSST) (Biotin) discontinued
Sign In for Pricing
View Details 
MBS1078806-01 1 mg (E-Coli)
Recombinant Spermophilus richardsonii Cytochrome b (MT-CYB), partial
Sign In for Pricing
View Details MBS1078806-02 1 mg (Yeast)
Recombinant Spermophilus richardsonii Cytochrome b (MT-CYB), partial
Sign In for Pricing
View Details CCR9-2621H 50 µg
Recombinant Human CCR9 Protein, His (Fc)-Avi-tagged
Sign In for Pricing
View Details